New drug tested for Tough-to-Treat prostate cancer
Disease control
Completed
This study tested the safety and initial effectiveness of an experimental drug called ARN-509 in men with advanced prostate cancer that had progressed despite standard hormone therapy. The first part of the study aimed to find a safe dose, and the second part tested that dose in …
Phase: PHASE1, PHASE2 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC